Establishing the role of tyrosine kinase 2 in cancer

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Übel, Caroline ^a   Mousset, Stephanie ^a   Trufa, Denis ^a   Sirbu, Horia ^a   Finotto, Susetta ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cancer; Cytokines; JAK STAT signalling; Lung cancer; Tumor therapy; TYK2

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; ERLOTINIB; FOCAL ADHESION KINASE 1; GEFITINIB; IMMUNOGLOBULIN E; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LESTAURTINIB; RUXOLITINIB; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT6 PROTEIN;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HUMAN; INFLAMMATORY DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; MAST CELL; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THROMBOCYTHEMIA;

EID: 84885433618     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22840     Document Type: Review

References (75)

1. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273-87; PMID:19290934; http://dx.doi.org/10.1111/ j.1600-065X.2008.00754.x.
2. Strobl B, Stoiber D, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci 2011; 16:3214-32; PMID:21622231; http://dx.doi.org/10.2741/3908.
3. Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 2010; 400:413-33; PMID:20478313; http://dx.doi. org/10.1016/j.jmb.2010.05.020.
4. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13:549-60; PMID:11070173; http://dx.doi. org/10.1016/S1074-7613(00)00054-6.
5. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13:561-71; PMID:11070174; http://dx.doi.org/10.1016/S1074-7613(00)00055-8.
6. Watford WT, O'Shea JJ. Human tyk2 kinase deficiency: another primary immunodeficiency syndrome. Immunity 2006; 25:695-7; PMID:17098200; http:// dx.doi.org/10.1016/j.immuni.2006.10.007.
7. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol 2006; 72:1538-46; PMID:16750817; http://dx.doi.org/10.1016/j.bcp.2006.04.013.
8. + T helper cell differentiation and inflammatory diseases. Cytokine 2009; 47:149-56; PMID:19648026; http://dx.doi. org/10.1016/j.cyto.2009.07.003.
9. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-62; PMID:12209125; http://dx.doi. org/10.1038/nrm909.
10. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109(Suppl):S121-31; PMID:11983158.
11. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992; 70:313-22; PMID:1386289; http://dx.doi.org/10.1016/0092-8674(92)90105-L.
12. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25:745-55; PMID:17088085; http:// dx.doi.org/10.1016/j.immuni.2006.09.009.
13. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012; 160:1055-7; PMID:22402565; http:// dx.doi.org/10.1016/j.jpeds.2012.01.056.
14. Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/ Th17 axes in vivo. J Immunol 2011; 187:181-9; PMID:21606247; http://dx.doi.org/10.4049/jimmunol. 1003244.
15. Wan J, Fu AK, Ip FC, Ng HK, Hugon J, Page G, et al. Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer's disease. J Neurosci 2010; 30:6873-81; PMID:20484629; http:// dx.doi.org/10.1523/JNEUROSCI.0519-10.2010.
16. Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K, et al. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol 2009; 183:7539-46; PMID:19917699; http://dx.doi.org/10.4049/jimmunol.0902740.
17. Spach KM, Noubade R, McElvany B, Hickey WF, Blankenhorn EP, Teuscher C. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J Immunol 2009; 182:7776-83; PMID:19494301; http://dx.doi. org/10.4049/jimmunol.0900142.
18. Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, et al. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol 2009; 29:815-25; PMID:19653082; http://dx.doi. org/10.1007/s10875-009-9320-x.
19. Strobl B, Bubic I, Bruns U, Steinborn R, Lajko R, Kolbe T, et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol 2005; 175:4000-8; PMID:16148148.
20. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshäuser G, Baccarini M, Donabauer B, et al. Central role for type I interferons and Tyk2 in lipopolysaccharideinduced endotoxin shock. Nat Immunol 2003; 4:471-7; PMID:12679810; http://dx.doi.org/10.1038/ni910.
21. Schleicher U, Mattner J, Blos M, Schindler H, Röllinghoff M, Karaghiosoff M, et al. Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol 2004; 34:519-29; PMID:14768057; http:// dx.doi.org/10.1002/eji.200324465.
22. Shaw MH, Freeman GJ, Scott MF, Fox BA, Bzik DJ, Belkaid Y, et al. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol 2006; 176:7263-71; PMID:16751369.
23. Seto Y, Nakajima H, Suto A, Shimoda K, Saito Y, Nakayama KI, et al. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 2003; 170:1077-83; PMID:12517976.
24. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18:693-704; PMID:22561833; http:// dx.doi.org/10.1038/nm.2755.
25. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 1997; 17(3A):1541-9; PMID:9179193.
26. Dyduch G, Kaczmarczyk K, Oko K. Mast cells and cancer: enemies or allies? Pol J Pathol 2012; 63:1-7; PMID:22535614.
27. Jensen-Jarolim E, Pawelec G. The nascent field of AllergoOncology. Cancer Immunol Immunother 2012; 61:1355-7; PMID:22911119; http://dx.doi. org/10.1007/s00262-012-1315-4.
28. Platzer B, Dehlink E, Turley SJ, Fiebiger E. How to connect an IgE-driven response with CTL activity? Cancer Immunol Immunother 2012; 61:1521-5; PMID:22042251; http://dx.doi.org/10.1007/s00262-011-1127-y.
29. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 2012; 61:1547-64; PMID:22139135; http://dx.doi.org/10.1007/s00262-011-1162-8.
30. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012; 32:1119-36; PMID:22493341.
31. Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide casecontrol study in Sweden. Eur J Cancer 2006; 42:3028-33; PMID:16945522; http://dx.doi.org/10.1016/j. ejca.2006.04.021.
32. Cooper GS, Kamel F, Sandler DP, Davey FR, Bloomfield CD. Risk of adult acute leukemia in relation to prior immune-related conditions. Cancer Epidemiol Biomarkers Prev 1996; 5:867-72; PMID:8922293.
33. Eriksson NE, Mikoczy Z, Hagmar L. Cancer incidence in 13811 patients skin tested for allergy. J Investig Allergol Clin Immunol 2005; 15:161-6; PMID:16261950.
34. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 1993; 22:976-82; PMID:8144310; http:// dx.doi.org/10.1093/ije/22.6.976.
35. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19:5662-79; PMID:11114747; http://dx.doi.org/10.1038/ sj.onc.1203925.
36. Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S, Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2008; 369:292-6; PMID:17920038; http://dx.doi.org/10.1016/j.bbrc.2007.08.160.
37. Song XC, Fu G, Yang X, Jiang Z, Wang Y, Zhou GW. Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics 2008; 7:163-9; PMID:17934210; http://dx.doi.org/10.1074/mcp.M700115-MCP200.
38. Zhu X, Lv J, Yu L, Zhu X, Wu J, Zou S, et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol 2009; 112:248-56; PMID:19007971; http://dx.doi. org/10.1016/j.ygyno.2008.09.045.
39. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114:1650-8; PMID:15578097.
40. Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, et al. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 2009; 69:203-11; PMID:19118004; http://dx.doi.org/10.1158/0008-5472.CAN-08-1705.
41. Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome coencapsulated with model tumor antigen. Int Immunol 2006; 18:425-34; PMID:16415100; http://dx.doi. org/10.1093/intimm/dxh381.
42. Sang QX, Man YG, Sung YM, Khamis ZI, Zhang L, Lee MH, et al. Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis. Clin Exp Metastasis 2012; 29:143-53; PMID:22116632; http://dx.doi. org/10.1007/s10585-011-9437-1.
43. Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, et al. The role of Tyk2 in regulation of breast cancer growth. J Interferon Cytokine Res 2011; 31:671-7; PMID:21864028; http://dx.doi. org/10.1089/jir.2011.0023.
44. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D, et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 2007; 67:465-73; PMID:17234753; http://dx.doi.org/10.1158/0008-5472.CAN-06-1736.
45. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111:4797-808; PMID:18270328; http://dx.doi. org/10.1182/blood-2007-09-113027.
46. Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K, et al. Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol 2002; 169:4707-11; PMID:12391177.
47. Gamero AM, Potla R, Wegrzyn J, Szelag M, Edling AE, Shimoda K, et al. Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem 2006; 281:16238-44; PMID:16601124; http://dx.doi.org/10.1074/jbc. M509516200.
48. Potla R, Koeck T, Wegrzyn J, Cherukuri S, Shimoda K, Baker DP, et al. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 2006; 26:8562-71; PMID:16982690; http://dx.doi. org/10.1128/MCB.00497-06.
49. Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS One 2011; 6:e19861; PMID:21625473; http://dx.doi.org/10.1371/journal. pone.0019861.
50. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296:1653-5; PMID:12040185; http://dx.doi.org/10.1126/science. 1071545.
51. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STATdependent gene regulation by cytokines. Drug News Perspect 2005; 18:243-9; PMID:16034480; http:// dx.doi.org/10.1358/dnp.2005.18.4.908658.
52. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663-71; PMID:17984313; http://dx.doi. org/10.1182/blood-2007-04-083402.
53. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010; 13:394-403; PMID:20506062.
54. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489:155-9; PMID:22820254; http://dx.doi.org/10.1038/nature11303.
55. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009; 106:8368-73; PMID:19416831; http://dx.doi.org/10.1073/ pnas.0903392106.
56. Suarez-Gestal M, Calaza M, Dieguez-Gonzalez R, Perez-Pampin E, Pablos JL, Navarro F, et al. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. Arthritis Rheum 2009; 60:2558-64; PMID:19714582; http://dx.doi.org/10.1002/art.24748.
57. Suarez-Gestal M, Calaza M, Endreffy E, Pullmann R, Ordi-Ros J, Sebastiani GD, et al.; European Consortium of SLE DNA Collections. Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res Ther 2009; 11:R69; PMID:19442287; http://dx.doi. org/10.1186/ar2698.
58. Nakagawa R, Yoshida H, Asakawa M, Tamiya T, Inoue N, Morita R, et al. Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J Immunol 2011; 187:4611-20; PMID:21957150; http://dx.doi.org/10.4049/jimmunol.1100649.
59. Matsunaga Y, Inoue H, Fukuyama S, Yoshida H, Moriwaki A, Matsumoto T, et al. Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. Biochem Biophys Res Commun 2011; 404:261-7; PMID:21111712; http:// dx.doi.org/10.1016/j.bbrc.2010.11.104.
60. Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, et al. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J Med Chem 2011; 54:284-8; PMID:21155605; http://dx.doi.org/10.1021/ jm101157q.
61. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66:9714-21; PMID:17018630; http://dx.doi.org/10.1158/0008-5472.CAN-05-4280.
62. Pensa S, Watson CJ, Poli V. Stat3 and the inflammation/ acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 2009; 14:121-9; PMID:19424782; http://dx.doi.org/10.1007/s10911-009-9124-x.
63. Li Q, Yang XH, Xu F, Sharma C, Wang HX, Knoblich K, et al. Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. Oncogene 2012; PMID:22824799; http://dx.doi.org/10.1038/ onc.2012.205.
64. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/ Janus kinase pathway in breast cancer. Breast Cancer Res 2007; 9:R32; PMID:17531096; http://dx.doi. org/10.1186/bcr1680.
65. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:29S-55S.
66. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-80; PMID:18815398; http://dx.doi.org/10.1056/NEJMra0802714.
67. Gorenstein LA, Sonett JR. The surgical management of stage I and stage II lung cancer. Surg Oncol Clin N Am 2011; 20:701-20; PMID:21986267; http://dx.doi. org/10.1016/j.soc.2011.07.009.
68. rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379-86; PMID:19632716; http://dx.doi.org/10.1016/S0140-6736(09)60737-6.
69. Felip E, Stahel RA, Pavlidis N; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-smallcell lung cancer (NSCLC). Ann Oncol 2005; 16(Suppl 1):i28-9; PMID:15888743; http://dx.doi.org/10.1093/ annonc/mdi821.
70. Hardy D, Cormier JN, Xing Y, Liu CC, Xia R, Du XL. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 2010; 5:90-8; PMID:19884853; http:// dx.doi.org/10.1097/JTO.0b013e3181c0a128.
71. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67:257-74; PMID:19914732; http://dx.doi.org/10.1016/j. lungcan.2009.10.012.
72. Serke M. [Lung cancer: targeted therapy]. Pneumologie 2007; 61:162-70; PMID:17342577; http://dx.doi. org/10.1055/s-2007-959159.
73. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 2012; 7:1417-22; PMID:22895139; http://dx.doi. org/10.1097/JTO.0b013e318260de8b.
74. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-92; PMID:16204011; http://dx.doi. org/10.1200/JCO.2005.02.7078.
75. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117:3846-56; PMID:18060032; http://dx.doi. org/10.1172/JCI31871.